Table 3.
Antidiabetic peptides for type 2 diabetes mellitus (T2DM).
| Antidiabetic Peptides | Hypoglycaemia | Weight Gain | Oedema | GI Effects | Lactic Acidosis | Liver Toxicity |
|---|---|---|---|---|---|---|
| Glipizide XL | 1+ | 1+ | 0 | ± | 0 | ± |
| Glyburide | 4+ | 2+ | 0 | ± | 0 | ± |
| Glimepiride | 2+ | 1+ | 0 | ± | 0 | ± |
| Repaglinide | 1+ | 1+ | 0 | 0 | 0 | 0 |
| Nateglinide | 1+ | ↓ | 0 | 0 | 0 | 0 |
| Metformin | 0 | ? | 0 | 2+ | 1+ | 0 |
| Acarbose | 0 | 0 | 0 | 3+ | 0 | ± |
| Miglitol | 0 | 0 | 0 | 3+ | 0 | 0 |
| Rosiglitazone | 0 | 3+ | 2+ | 0 | 0 | 0 * |
| Pioglitazone | 0 | 3+ | 2+ | 0 | 0 | 0 * |
0 = none, ± = very infrequent, 1+ = infrequent, 2+ = occasional, 3+ = moderate, 4+ = significant, ↓ = decrease, ? = unknown. * The liver function monitoring recommendation was adapted from [4] articles published under an open access Creative Common CC BY license, MDPI, 2018.